397 related articles for article (PubMed ID: 9606481)
1. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
Martineau P; Tawil N
Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparins for the treatment of deep-vein thrombosis.
Cziraky MJ; Spinler SA
Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
Agnelli G; Sonaglia F
Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
[TBL] [Abstract][Full Text] [Related]
5. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
Cheer SM; Dunn CJ; Foster R
Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
Wells PS; Anderson DR; Rodger MA; Forgie MA; Florack P; Touchie D; Morrow B; Gray L; O'Rourke K; Wells G; Kovacs J; Kovacs MJ
Arch Intern Med; 2005 Apr; 165(7):733-8. PubMed ID: 15824291
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic equivalency of low-molecular-weight heparins.
McCart GM; Kayser SR
Ann Pharmacother; 2002 Jun; 36(6):1042-57. PubMed ID: 12022908
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparins in the prevention of deep-vein thrombosis in general surgery.
Breddin HK
Semin Thromb Hemost; 1999; 25 Suppl 3():83-9. PubMed ID: 10549721
[TBL] [Abstract][Full Text] [Related]
9. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
Avritscher EB; Cantor SB; Shih YC; Escalante CP; Rivera E; Elting LS
Support Care Cancer; 2004 Jul; 12(7):531-6. PubMed ID: 14986076
[TBL] [Abstract][Full Text] [Related]
10. The low molecular weight heparin, tinzaparin, in thrombosis and beyond.
Mousa SA
Cardiovasc Drug Rev; 2002; 20(3):199-216. PubMed ID: 12397367
[TBL] [Abstract][Full Text] [Related]
11. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
Davis R; Faulds D
Drugs Aging; 1997 Apr; 10(4):299-322. PubMed ID: 9108990
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.
Dolovich LR; Ginsberg JS; Douketis JD; Holbrook AM; Cheah G
Arch Intern Med; 2000 Jan; 160(2):181-8. PubMed ID: 10647756
[TBL] [Abstract][Full Text] [Related]
13. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
Mismetti P; Quenet S; Levine M; Merli G; Decousus H; Derobert E; Laporte S
Chest; 2005 Oct; 128(4):2203-10. PubMed ID: 16236875
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of different low-molecular weight heparins used at therapeutic dose.
Gouin-Thibault I; Pautas E; Siguret V
Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
[TBL] [Abstract][Full Text] [Related]
15. Structured benefit-risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer.
Kürzinger ML; El-Haddad C; Gouin-Soboleva T; Fazekas Z; Granados D; Benito-Garcia E; Djoudi Y
Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5795. PubMed ID: 38680090
[TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparins for acute coronary syndromes.
Spinler SA; Nawarskas JJ
Ann Pharmacother; 1998 Jan; 32(1):103-10. PubMed ID: 9475828
[TBL] [Abstract][Full Text] [Related]
17. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
Dunn CJ; Goa KL
Pharmacoeconomics; 1996 Aug; 10(2):179-90. PubMed ID: 10163420
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetics of LMWHs.
Samama MM; Gerotziafas GT
Semin Thromb Hemost; 2000; 26 Suppl 1():31-8. PubMed ID: 11011804
[TBL] [Abstract][Full Text] [Related]
19. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight heparins.
Bergqvist D
J Intern Med; 1996 Aug; 240(2):63-72. PubMed ID: 8810931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
